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Whereas cells productively infected with human immunodeficiency virus type 1 (HIV-1) decay rapidly in the setting of
highly active antiretroviral therapy (HAART), latently infected resting CD4
þ T cells decay very slowly, persisting for the
lifetime of the patient and thus forming a stable reservoir for HIV-1. It has been suggested that the stability of the
latent reservoir is due to low-level viral replication that continuously replenishes the reservoir despite HAART. Here, we
offer the first quantitative study to our knowledge of inflow of newly infected cells into the latent reservoir due to viral
replication in the setting of HAART. We make use of a previous observation that in some patients on HAART, the
residual viremia is dominated by a predominant plasma clone (PPC) of HIV-1 not found in the latent reservoir. The
unique sequence of the PPC serves as a functional label for new entries into the reservoir. We employ a simple
mathematical model for the dynamics of the latent reservoir to constrain the inflow rate to between 0 and as few as 70
cells per day. The magnitude of the maximum daily inflow rate is small compared to the size of the latent reservoir, and
therefore any inflow that occurs in patients on HAART is unlikely to significantly influence the decay rate of the
reservoir. These results suggest that the stability of the latent reservoir is unlikely to arise from ongoing replication
during HAART. Thus, intensification of standard HAART regimens should have minimal effects on the decay of the
latent reservoir.
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Introduction
The discovery of a stable latent reservoir for human
immunodeﬁciency virus type 1 (HIV-1) [1–5] in resting
CD4
þ T cells uncovered a major obstacle to curing HIV-1
infection and revealed limitations of previous analytical
predictions concerning eradication [6]. This reservoir persists
despite years of highly active antiretroviral therapy (HAART)
[7–9]. The observation that suspension of treatment leads to
rapid rebound in viral load [10] may reﬂect the persistence of
latently infected CD4
þ T cells and possibly other viral
reservoirs, as well as some degree of active viral replication
that continues despite HAART [11–17].
The mechanism underlying the stability of the latent
reservoir remains unclear. Some investigators have argued
that residual viral replication continuously reseeds the latent
reservoir [11,18,19], thereby providing long-term stability.
With extremely sensitive methods, a low level of free virus can
be detected in the plasma of patients on HAART who have
suppression of viremia to below the limit of detection of
ultrasensitive clinical assays [12,20–24]. In addition, many
patients on HAART have transient episodes of detectable
viremia termed blips [25–27]. These ﬁndings suggest that
patients on HAART have a low level of viremia that may
replenish the latent reservoir in resting CD4
þ T cells through
de novo infection of cells that then enter the reservoir. The
other major explanation for the persistence of the latent
reservoir is that the stability arises from the intrinsic dynamic
properties of the latently infected cells. Because the reservoir
consists of resting memory T cells [28], which form the basis
of life-long immunity to previously experienced pathogens,
the cells that harbor latent HIV-1 are fundamentally long-
lived. Latently infected cells are protected from host immune
responses because there is little or no transcription of viral
genes in these cells [29,30]. The fact that some patients do not
develop drug resistance despite long periods of HAART
supports the idea that the virus can persist through
mechanisms that do not involve continuous cycles of
replication. Thus, the intrinsic stability of latently infected
cells provides a plausible alternative explanation for the
stability of the reservoir [21,31].
Curing HIV-1 infection will require elimination of the
latent reservoir. It is therefore critical to understand which of
these potential mechanisms are responsible for its stability.
As a step in this direction, we have used mathematical
modeling to understand the dynamics of the reservoir.
Mathematical models have proven useful for analysis of
several aspects of HIV-1 infection, including measurement of
Editor: Susan Ross, University of Pennsylvania School of Medicine, United States of
America
Received February 9, 2007; Accepted July 9, 2007; Published August 31, 2007
Copyright:  2007 Sedaghat et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: HAART, highly active antiretroviral therapy; HIV, human immuno-
deficiency virus; PPC, predominant plasma clone; RT, reverse transcriptase
* To whom correspondence should be addressed. E-mail: rsiliciano@jhmi.edu
PLoS Pathogens | www.plospathogens.org August 2007 | Volume 3 | Issue 8 | e122 1165the turnover of different T cell subsets [32–35] and the
response to therapy [6,36–44]. In this study, we take
advantage of (and experimentally extend) a data set consist-
ing of HIV-1 sequences from patients on HAART who
maintain a distinctive pool of plasma virus [45]. In these
patients, most of the residual viremia is comprised of a single
predominant plasma clone (PPC) that is speciﬁc in sequence
to each patient. Using this PPC as a label and a simple
mathematical model, we take a maximum likelihood ap-
proach to quantitatively constrain the rate at which de novo
infection replenishes the latent reservoir.
Materials and Methods
Experimental Procedures
The procedures for obtaining and analyzing the sequences
used in this study have been described in detail elsewhere
[45]. Brieﬂy, we studied asymptomatic HIV-1-infected adults
who had achieved suppression of viremia to ,50 copies/ml on
a stable HAART regimen for  6 mo and were willing to make
frequent study visits. We previously described ﬁve patients
who each had a PPC. For this present study, we exclude two of
these patients (pt. 113 and pt. 139) due to a lack of sufﬁcient
follow-up sequence information beyond the intensive sam-
pling period. The characteristics and treatment histories of
the patients included in our analysis (pts. 135, 148, and 154)
are representative of many HAART patients (exhibiting
frequent and infrequent blips, on different HAART regimens
with viral suppression from roughly 1.5 y to over 6 y) as
previously described [46]. One of these patients, pt. 154,
experienced (previous to this study) sequential failure of AZT
monotherapy followed by failure of a three-drug HAART
regimen and also exhibited multiple blips during the course
of the study. Of all study participants, then, pt. 154 best
represents the potential for ongoing viral replication (and
therefore replenishment of the latent reservoir) in the setting
of HAART.
To allow consistent ampliﬁcation and sequencing of the
small number of viral genomes present in the plasma of
patients with viral loads below 50 copies/ml, plasma virus was
ﬁrst pelleted by ultracentrifugation, and then analyzed by
limiting dilution reverse transcriptase (RT)-PCR, cloning, and
sequencing using a previously described ultrasensitive geno-
typing method [45]. Viruses persisting in the resting CD4
þ T
cell reservoir were analyzed by a novel limiting dilution PCR
assay [45]. Resting CD4
þT cells were puriﬁed from peripheral
blood mononuclear cells by magnetic bead depletion as
previously described [45]. As we have previously shown [3],
these cells do not produce virus without stimulation and
therefore by deﬁnition harbor latent virus. A segment of the
pol gene encompassing all of protease and the ﬁrst 219 amino
acids of RT was ampliﬁed with nested PCR under limiting
dilution conditions that ensure that each positive reaction
has a ;90% probability of being clonal. Products of positive
PCR reactions were directly sequenced. Reactions containing
more than one distinct template were identiﬁed by exami-
nation of chromatograms and excluded from the analysis.
As described previously, sequence analysis was carried out
using techniques designed to avoid PCR resampling and PCR
error [45]. Independent sequences that were identical to one
another throughout this region of RT were identiﬁed using
Varplot (kindly provided by Stuart Ray, Johns Hopkins
University). Care was taken to avoid PCR errors in the
sequence analysis. Proviral DNA samples were analyzed by
limiting dilution PCR and direct sequencing. This approach
has the advantage of eliminating PCR errors except for those
that occur in the ﬁrst or second cycle. For plasma virus, RT-
PCR reactions were set up at limiting dilution, and positive
reactions were cloned. Multiple clones were sequenced from
each reaction. This allowed ready recognition of PCR errors
as mutations appearing in only one clone from a set of clones
obtained from a limiting dilution reaction. PCR errors were
detected at a frequency that was no greater than the
frequency expected based on a formal error analysis carried
out on viral RNA from a cloned laboratory isolate of HIV-1
that was ampliﬁed under the same conditions [45]. These
errors were reverted to patient consensus. Phylogenetic
analysis was carried out on a segment of the RT coding
region representing amino acids 38–219 as previously
described [45]. For each time point, pie charts were
constructed in which distinct taxa present at that time point
were represented as separate slices, with the size of each slice
being proportional to the number of independent clones
isolated with that sequence.
The number of latently infected cells carrying replication-
competent virus was quantiﬁed as previously described [47].
The number of HIV DNA-containing resting CD4
þT cells was
determined by quantitative real-time PCR [45].
Mathematical Models
To evaluate replenishment quantitatively, we used a simple
mathematical model to represent the dynamics of the latent
reservoir in patients on HAART who had suppression of
viremia to ,50 copies/ml and whose residual viremia was
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Author Summary
Latently infected resting CD4
þT cells represent a stable reservoir for
human immunodeficiency virus (HIV). When HIV-infected individuals
are treated with highly active antiretroviral therapy (HAART), this
latent reservoir decays slowly, with a half-life of up to 44 months. As
a result, latently infected resting CD4
þ T cells represent the major
known barrier to eradication of HIV infection. Two factors are
believed to contribute to the stability of the latent reservoir in the
setting of HAART: replenishment by low-level viral replication and
the intrinsic stability of resting memory CD4
þ T cells. Unfortunately,
it has not been possible to measure replenishment of this latent
reservoir. In this study, we take advantage of a cohort of patients on
HAART whose plasma virus consists largely of one (patient-specific)
predominant plasma clone (PPC) that is grossly underrepresented in
resting CD4
þ T cells. We use the PPC as a label for ongoing viral
replication by observing the accumulation of the PPC in resting
CD4
þ T cells over time in each patient. Analysis of the rate at which
the PPC accumulates in resting CD4
þ T cells allows us to
quantitatively infer the maximum inflow of cells into the latent
reservoir for HIV. Thus, we are able to provide the first quantitative
constraint to our knowledge on the replenishment rate of the latent
reservoir in the setting of HAART. Our results indicate that the rate of
replenishment is very small and likely not a source of stability in the
setting of HAART. These results have important implications
regarding therapeutic options for purging the resting CD4
þ T cell
reservoir and curing HIV infection. Specifically, these results suggest
that the intrinsic stability of latently infected resting CD4
þ T cells,
and not low-level viral replication, must be targeted therapeutically
in order to achieve eradication of the latent reservoir.largely composed of a PPC. Because only a small number of
plasma virus sequences can be obtained from a given blood
sample when the viral load is below 50 copies/ml, patients
underwent intensive (every other day) plasma sampling over
a 3-mo period, and data from this period of intensive
sampling were pooled. Consistent with our sequencing data,
we assumed that there were no latently infected cells
containing PPC at the beginning of the 3-mo sampling
period. Otherwise, we did not make any assumptions about
the origin of the PPC. We make the conservative assumption
that the PPC ﬁrst appears at the beginning of the
observation period (time t ¼ 0), despite the fact that the
PPC could have been present before we detected it.
Sequencing and ﬁtness studies (including direct examination
of env, RT, and protease genes) have revealed no signiﬁcant
functional differences between the PPC and other sequences
from the relevant patient [45]. Furthermore, we have
previously detected the PPC in resting CD4
þ T cells [45]
(Table 1), albeit at a very low frequency, suggesting that the
PPC is replication competent. Therefore, we assume that the
PPC is infectious and that once the PPC appears in the
plasma, it should begin entering the latent reservoir if there
is any inﬂow into the reservoir. We assume that the PPC has
permanently disappeared from the plasma (and thus can no
longer enter the reservoir) after a period of time, te. In order
to be maximally conservative, we allow te to be at most the
period of time that we experimentally observed the PPC in
each patient’s plasma (although it is not certain that the PPC
has entirely disappeared at later time points). Because we use
the PPC as a label for new entrants into the latent reservoir,
we use a previously described mathematical model used for
tracking labeled cells in studies of T cell dynamics in the
setting of HIV infection [48,49]. Our model consists of two
state variables representing the fraction of latently infected
cells containing PPC proviruses (L1) and latently infected
cells containing all other proviruses (L2) where
dL
dt
¼
dðL1 þ L2Þ
dt
¼ kin   koutðL1 þ L2Þ; ð1Þ
where kin is the rate constant for the entry of free viruses into
the latent pool and kout is the decay rate of latently infected
cells. Equation 1 has solution
LðtÞ¼½ Lð0Þ K e koutt þ K; ð2Þ
where we introduce K ¼ kin
kout :
We extend this simple model of reservoir dynamics so that
we consider L1(t) and L2(t) separately. We assume that these
two populations of latently infected cells have the same
kinetic properties and that the rate of replenishment of the
latent reservoir is proportional to the fraction of the plasma
virus of a given type. This model is described by a system of
two ordinary differential equations,
dL1
dt
¼ kinf   koutL1; ð3Þ
dL2
dt
¼ kinð1   fÞ koutL2; ð4Þ
where f is the fraction of plasma virus that consists of the
PPC. Equations 3 and 4 may be solved explicitly:
L1ðtÞ¼½ L1ð0Þ Kf e koutt þ Kf; ð5Þ
L2ðtÞ¼½ L2ð0Þ Kð1   fÞ e koutt þ Kð1   fÞ: ð6Þ
Using Equations 5 and 6, we can predict the dynamics of
each latent reservoir population and therefore the fraction of
latently infected cells in each pool at various time points
while the PPC was present. At time points t after the PPC had
disappeared from the plasma (at time te), the two latent
reservoir pools are described by the equations
dL1
dt
¼  koutL1; ð7Þ
dL2
dt
¼ kin   koutL2; ð8Þ
which have explicit solutions:
L1ðtÞ¼L1ðteÞe koutðt teÞ; ð9Þ
L2ðtÞ¼Kð1   e koutðt teÞÞþL2ðteÞe koutðt teÞ: ð10Þ
Maximum Likelihood Estimation
The fraction of latently infected cells at time t that should
contain the predominant plasma clone, UPPC,c a nb e
calculated from Equations 9 and 10 as
UPPC ¼
L1
L1 þ L2
¼

e koutt½L1ð0ÞþKfðekoutt   1Þ 

=

Ke kouttðe koutte   ekouttÞþ½ L2ð0Þe koutt þ Kð1   fÞð1   e kouttÞ 
þ e koutt½L1ð0ÞþKfðekoutt   1Þ 

:
ð11Þ
To be conservative, the initial number of latently infected
cells containing PPC DNA (L1(0)) was set to zero for each
patient. Because blood samples from time t ¼ 0w e r e
Table 1. Presence of a PPC in the Plasma and Resting CD4
þ T Cells of Patients on HAART
Patient Characteristics Patient 135 Patient 148 Patient 154
% PPC in the plasma 79.1 93.6 72.1
Study day 174 285 196 376 153 410 550 998
Time since detection of PPC (days) 120 231 162 342 123 380 520 973
Time since end of intensive sampling (days) 30 141 72 252 33 290 430 883
Number of reservoir sequences obtained 103 65 48 50 38 22 7 163
Number of reservoir sequences identical to PPC 0 0 0 0 0 1 0 0
doi:10.1371/journal.ppat.0030122.t001
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containing all other viral DNA sequences (L2(0)) was
determined by extrapolation from experimental measure-
ments by limiting dilution PCR at various time points for
each patient (Table 2). We assume that the probability of
ﬁnding k PPC cellular sequences out of n total latent reservoir
sequences follows a binomial distribution, with the proba-
bility of success at time t set to the solution of Equation 11 at
time t:
PðkÞ¼
n
k

Uk
PPCð1   UPPCÞ
n k: ð12Þ
We used a maximum likelihood approach in order to ﬁnd
the value of kin most consistent with data collected from each
patient [50]. Brieﬂy, for speciﬁc values of kout, likelihood
estimates, P(k), were calculated for a large range of kin values
from Equation 12 using data collected from patients 135, 148,
and 154. The kin value corresponding to the maximum
likelihood estimate was designated as the most likely kin value.
We report analyses of patients that yielded informative
results for kin (i.e., kin   koutL).
All simulations and calculations were performed with
MATLAB version 7.2.0.232 (http://www.mathworks.com/).
Results
Application of the Model towards Understanding
Reservoir Dynamics
In a previous report, we described a population of HIV-1-
infected individuals on HAART who had suppression of
viremia to less than 50 copies/ml for an average of 34 mo [46].
Sequences of the residual plasma virus were obtained from
these individuals by intensive sampling (three times per week)
over a 3-mo period as well as at various intervals afterward
for more than 1 y. Sequences from proviruses in resting CD4
þ
T cells (from our previous work, we know that these
sequences are a reasonable surrogate for rescuable virus in
the same population of cells [45]) were obtained at the
beginning and end of the period of intensive sampling. In half
of these patients, a single, homogenous but distinct viral
sequence constituted a large fraction of the residual viremia
but was profoundly underrepresented within sequences from
resting CD4
þ T cells at baseline (Figure 1). Linkage analysis
suggested that this predominant plasma sequence actually
represented a single PPC [45]. Because the PPC sequence was
easily and speciﬁcally distinguishable from other sequences as
a single sequence that was repeatedly detected in the plasma,
this situation provided the ideal setting for determining
whether the residual viremia could replenish the latent
reservoir. Since most of the residual viremia was comprised
of a unique genotype rarely found in resting CD4
þ T cells,
entry of a substantial number of these plasma viruses into the
latent reservoir at later time points could be readily detected.
Therefore, we were able to employ this unique plasma virus
population as a functional label for measuring the rate of
replenishment for the latent reservoir in the setting of
HAART.
In order to ﬁnd the kin value most consistent with each
patient’s data, we take a maximum likelihood approach. To
calculate a likelihood estimate for each kin tested, however, we
must approximate kout. The dynamics of the latent reservoir
may behave according to one of three regimes (described in
Text S1), depending on the magnitude of koutL(t) compared to
kin (Figure 2). In order to cover the most likely kin values for all
possible levels of replication in the setting of HAART, we
approximate kout for when the latent reservoir decays
exponentially (kout ¼ lnð2Þ=t1
2 = , where t1
2 = is an experimentally
determined half-life of the latent reservoir) and for when the
reservoir does not decay (kout ¼ kin/L(0)) (regimes 1 and 2,
respectively).
Calculation of the Maximum Replenishment Rate of the
Latent Reservoir
For each time point when cellular sequences were obtained,
the most likely kin was chosen as the one with the maximum
likelihood estimate, given the data (Table 1). We also
calculated a 95% conﬁdence interval around this value and
use the upper bound of the 95% conﬁdence interval as a
conservative constraint on the maximum value of kin.
Experimentally, at all but one time point, we found no PPC
sequencesinthelatentreservoir.Consequently,themostlikely
value of kin calculated by the maximum likelihood approach
wasequaltozerocellsperday.However,thefactthatwefound
no PPC sequences in the latent reservoirs of our patients at
these time points does not deﬁnitively indicate that there were
no PPC sequences in the reservoir. In order to assign a more
conservative frequency for the PPC sequence within the latent
reservoir, we repeated all likelihood analyses with an add-one
estimator [51], where 1 was added to the number of cellular
PPC sequences obtained at each time point and 2 was added to
the total number of cellular sequences obtained at each time
point. Because the add-one approach already overestimates
the presence of the PPC in the latent reservoir, the most likely
kin calculated with the add-one estimator (mean value and not
upper bound of the 95% conﬁdence interval) is used as a
conservative constraint on the reservoir inﬂow rate. To
calculate the ﬂow of replication-competent viruses into the
latent reservoir, each patient’s calculated kin values were
multiplied by a, the experimentally determined ratio of cells
carrying replication-competent virus to cells carrying HIV-1
DNA (Table 2). From this point forward, kin will refer to the
ﬂow of replication-competent virus into the latent reservoir.
For the case when kout dominates reservoir decay, we set kout
¼ 0.000525 day
 1, which reﬂects the previously reported 44-
mo half-life of the latent reservoir. Initially, we assumed that
the PPC was present for only the 90-d intensive sampling
period despite the fact that two of the three patients
maintained the PPC beyond this time. Under these assump-
tions, our maximum likelihood analysis found a most likely
reservoir inﬂow rate of 0 cells/day, with an upper 95%
Table 2. Initial Latent Reservoir Size, L2(0), under Different
Reservoir Half-Life Assumptions for Patients on HAART
Patient L2(0) for 44-mo Half-Life
a L2(0) for 6-mo Half-Life
a a
b
135 44.48 114.77 0.013
148 85.30 213.04 0.007
154 176.35 1491.00 0.037
aHIV DNA copies/10
6 resting CD4
þ T cells as determined by limiting dilution PCR.
bThe number of latently infected cells carrying replication-competent virus per HIV DNA-
containing resting CD4
þ T cell.
doi:10.1371/journal.ppat.0030122.t002
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Limited Replenishment of HIV Reservoirconﬁdence bound of 151 cells per day in pt. 135 (Table 3).
The add-one estimator predicted a most likely kin of 94 cells
per day in this patient. Similar rates were observed for pt.
148, and slightly higher rates were observed for pt. 154. Pts.
135 and 154 both maintained the PPC in the plasma at levels
comparable to or above f beyond the intensive sampling
period (until study day 174 for pt. 135 and day 922 for pt. 154)
(unpublished data). To more accurately reﬂect the persis-
tence of the PPC, we repeated the maximum likelihood
analysis and assumed the PPC was present from time zero
until the last study day when the PPC was observed in the
plasma. Under this assumption, we again found a most likely
inﬂow rate of 0 cells/day for pt. 135. Using the upper bound of
the 95% conﬁdence interval, we found that the data are
consistent with kin up to 111 cells per day (Table 3). The add-
one estimate predicts the data to be consistent with kin up to
70 cells per day in this patient. Similar or slightly higher rates
were calculated for the other patients.
Because the true decay rate of the latent reservoir remains
controversial, we repeated the above analyses for kout¼0.0039
day
 1 (Table 3), which reﬂects a 6-mo half-life for the latent
reservoir, the fastest reservoir decay rate reported [19,52]. By
performing our analysis for the slowest (44-mo half-life) and
fastest (6-mo half-life) reported reservoir decay rates, we
Figure 1. PPCs Show Limited Entry into Resting CD4
þ T Cells of Patients on HAART
(A and B) Results are shown for two patients, pt. 148 (A) and pt. 154 (B). The heterogeneity of the latent reservoir in comparison to the homogeneity of
the plasma virus in these patients is represented with pie charts in which distinct genotypes are indicated in different colors. The PPC for each patient is
shown in red. Intensive sampling of the plasma virus was carried out by sampling three times per week over a 3- to 4-mo period as indicated by the thin
vertical marks on the time line. For pt. 154, additional samples of plasma virus (small circles) were obtained before and on several occasions after the
period of intensive sampling. These document the persistence of the PPC for a minimum of approximately 900 d. Sampling of proviruses in resting
CD4
þ T cells was carried out before and on multiple occasions after the period of intensive plasma sampling. With one exception (*), all of the cellular
sequences remained distinct from the PPC. The numbers below each circle represent the number of independent sequences analyzed. For pt. 154, the
plasma samples after study day 900 were analyzed by RT-PCR of the env gene. Previously, linkage studies [45] allowed us to identify the PPC in the env
sequences. Phylogenetic analysis of these sequences is described in detail elsewhere [45].
doi:10.1371/journal.ppat.0030122.g001
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Limited Replenishment of HIV Reservoircover the entire range of possible kin values. With a 6-mo
reservoir half-life and the assumption of the 90-d step input
of the PPC, kin was constrained to up to 335 cells per day by
the data for pt. 135, with the add-one estimate constraining
kin to 209 cells per day. Repeating the analysis for
experimentally determined patient-speciﬁc PPC inputs, we
found kin to be constrained to up to 232 cells per day by the
data and 147 cells per day with the add-one likelihood
estimate for this patient.
In our analysis above, we used an approximation of kout
based on an assumed exponential decay of the latent
reservoir (regime 1). The true range of kin values for each
patient is bounded by the range of kin values calculated for
regime 1 (latent reservoir decays exponentially) and regime 2
(latent reservoir is at steady state). We therefore calculated
kout for the latent reservoir at steady state and repeated the
analyses described above (Table 3). We initially assumed a 90-
d step input of the PPC into the plasma of each patient and
found that our analysis found a most likely reservoir inﬂow
rate of 0 cells/day, with an upper 95% conﬁdence bound of
151 cells per day. The add-one estimator predicted that the
data are consistent with a most likely kin equal to 96 cells per
day. When we extended the period of PPC presence in the
plasma until the last study day when it was last observed for
each patient, we found that the data constrained kin to be up
to 112 cells per day for pt. 135, with the add-one estimator
constraining kin to be up to 72. The kin estimates for the
steady-state assumption are not signiﬁcantly different from
the kin estimates made above with kout dictating the reservoir
decay rate, suggesting that the calculated maximum kin values
consistent with all of the data are good approximations for
the true maximum rate of inﬂow into the latent reservoir.
The Maximum Daily Flow of Cells into the Latent Reservoir
during HAART Is a Small Fraction of the Patients’ Reservoir
Size
It is also helpful to view the maximum absolute ﬂow rate
into the reservoir in the context of the overall reservoir size
in each patient. We approximate the percentage of the total
reservoir that daily reservoir inﬂow represents by normaliz-
ing the daily reservoir inﬂow (the upper bound of the 95%
conﬁdence intervals for each kin calculated based on the pure
data or the most likely kin calculated with an add-one estimate
in Table 3) with the starting number of replication-
competent cells in the latent reservoir (a(L1(0) þ L2(0)))
(Table 4). Our calculations indicate that for each patient,
maximum daily ﬂow of infected cells into the reservoir is very
small compared to the total reservoir size. In fact, most
maximum kin calculations were on the order of 0.01%–0.1%
of the starting total reservoir size and even as low as ,
0.001%. Because the total reservoir size decreases over time
and we assume a constant kin, the values in Table 4 increase
over time. On the time scale of when samples were taken
from patients, however, none of the values in Table 4 would
increase by more than 2-fold if assuming a 44-mo reservoir
half-life, and most would not increase by more than 4-fold if
assuming a 6-mo reservoir half-life.
The Maximum Daily Flow of Cells into the Latent Reservoir
during HAART Is Considerably Reduced Compared to the
Pre-HAART Reservoir Inflow
We also consider whether our predicted maximum daily
inﬂow of cells into the latent reservoir during HAART
reﬂects a reduction from the predicted pre-HAART inﬂow.
We have previously described how long each patient in this
study had consistently suppressed viremia (79 mo for pt. 135,
35 mo for pt. 148, and 17 mo for pt. 154 from Table 1 of [45])
prior to enrollment in our study, and we have measured the
size of each patient’s latent reservoir at the beginning of our
study (Table 2). From these values, and assuming a reservoir
half-life of 44 mo (corresponding to kout¼0.000525 day
 1), we
are able to back calculate the most recent size of each
patient’s pre-therapy latent reservoir,  Lpre HAART. The steady-
state, pre-HAART reservoir inﬂow for each patient may be
calculated by kout Lpre HAART. Based on this calculation and our
lowest predicted upper bound on kin for each patient in Table
3, we ﬁnd that HAART has reduced the daily inﬂow into the
latent reservoir by at least (since we calculate the maximum
reservoir inﬂow rate) a factor of 10.7 for pt. 135, 2.2 for pt.
148, and 18.8 for pt. 154, if we assume a 44-mo half-life for the
resting CD4
þ T cell reservoir. These fold reductions are
several orders of magnitude larger if we assume a 6-mo half-
life. These results indicate that HAART can drastically reduce
the ﬂow of cells into the resting CD4
þ T cell reservoir.
Discussion
The latent reservoir for HIV-1 in resting CD4
þT cells is the
primary known barrier to eradication of HIV-1 infection.
Figure 2. Dynamics of the Latent Reservoir (Black) L for the Three
Described Regimes with Respect to the Steady State of L (Red) and a
Purely Exponential Decay Defined by fðtÞ¼Lð0Þe koutt (Blue)
(A) Regime 1; koutL(t)   kin.
(B) Regime 2; koutL(t) ¼ kin.
(C) Regime 3; koutL(t) ’ kin and koutL(t) . kin.
doi:10.1371/journal.ppat.0030122.g002
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Limited Replenishment of HIV ReservoirTherefore, eradication of HIV-1 infection depends on
successful purging of the latent reservoir from an infected
individual. Unfortunately, experimental evidence has shown
that the latent reservoir is highly stable. Whereas the half-
lives of other types of infected cells in the setting of HAART
are on the order of days to weeks, the half-life of the latent
reservoir has been reported to be on the order of months to
years [7–9]. The longevity of the reservoir requires HIV-1-
positive individuals to remain on HAART for their entire
lives [53].
The basis for the stability of the latent reservoir is
controversial. Some reports have shown an increase in the
reservoir decay rate with an intensiﬁed HAART regimen [18],
suggesting that low-level viral replication continuously
replenishes the reservoir [11,18,19]. Because the latent
reservoir resides within memory CD4
þ T cells, which are
inherently long-lived cells, some have hypothesized that the
latent reservoir’s longevity stems from its intrinsic stability
[7–9,20,28]. Longitudinal studies of patients on standard
HAART have shown no generation of new drug-resistant
virus in plasma, suggesting a halt in viral replication [21].
These studies support the notion that the latent reservoir is
intrinsically stable, consistent with the known properties of
memory CD4
þ T cells. It is difﬁcult to ﬁnd direct, exper-
imental support for either argument, however, due to the lack
of a readily accessible experimental model.
Opportunities do arise when patient-derived data may be
used to gain unique insights into the latent reservoir. In this
study, we offer a quantitative glimpse into the replenishment
of the latent reservoir in the setting of HAART. Although
several studies have suggested that reservoir replenishment
might occur during HAART [11,18,19], there has been no
quantitation of the replenishment rate. This has been due in
part to the fact that there is no way of uniquely labeling
latently infected resting CD4
þ T cells and subsequently
following that label. In this study we take advantage of a
previously reported phenomenon where a unique, patient-
speciﬁc viral sequence (PPC) dominated the residual plasma
virus but could not be readily found in the patient’s activated
or resting CD4
þ T cells [17,45]. For our study, we use and
extend a previously reported, exhaustive data set of plasma
and proviral sequences [45]. We hypothesized that replenish-
ment of the latent reservoir by viral replication in the
presence of the PPC would eventually lead to incorporation
of the PPC into the latent reservoir. We used a simple
mathematical model of latent reservoir dynamics to constrain
the maximum rate of reservoir replenishment by viral
replication in the setting of HAART.
Our model was constructed with as few assumptions as
possible regarding the nature of reservoir dynamics. Our
model does rely on the assumption that the PPC is replication
competent, or at least capable of infecting and integrating
into the genome of a CD4
þT cell. Our previous study strongly
suggested that each patient’s PPC was not different than
other patient-speciﬁc plasma virus sequences in functionality
(by direct examination of env, RT, and protease genes) or
resistance to antiretroviral drugs or host-mediated immune
responses [45]. Furthermore, detection of the PPC at a low
frequency in resting CD4
þT cells [45] was highly suggestive of
the idea that the PPC is replication competent. We therefore
Table 3. Estimation of Patient-Specific, Maximum Reservoir Inflow Rates
Case
a Patient Reservoir
Half-Life
(Months)
PPC Input
Period
(Days)
kin (95%
CI), Cells/Day
Add-One Estimator
kin (95% CI),
Cells/Day
1 135 44 90 0 (0, 151) 94 (23, 338)
148 44 90 0 (0, 246) 145 (36, 601)
154 44 90 474 (78, 3,830) 3,304 (1,195, 13,335)
2 135 44 120 0 (0, 111) 70 (17, 246)
148 44 55 0 (0, 463) 249 (62, 1,281)
154 44 897 44 (4, 237) 226 (89, 540)
3 135 6 90 0 (0, 335) 209 (53, 785)
148 6 90 0 (0, 572) 319 (80, 1,476)
154 6 90 7,419 (1,110, 53,132) 42,176 (14,326, 61,727)
4 135 6 120 0 (0, 232) 147 (36, 532)
148 6 55 0 (0, 1,284) 599 (147, 3,855)
154 6 897 59 (7, 314) 303 (122, 744)
5
b 135 ‘ 90 0 (0, 151) 96 (23, 346)
148 ‘ 90 0 (0, 244) 146 (37, 597)
154 ‘ 90 474 (77, 6,031) 3,630 (1,258, 22,785)
6
b 135 ‘ 120 0 (0, 112) 72 (17, 251)
148 ‘ 55 0 (0, 498) 250 (62, 5,507)
154 ‘ 897 56 (7, 289) 278 (111, 640)
aCases (based on assumptions used for the model):
1, 44-mo half-life, 90-d step input.
2, 44-mo half-life, full presence.
3, 6-mo half-life, 90-d step input.
4, 6-mo half-life, full presence.
5, steady-state, 90-d step input.
6, steady-state, full presence.
bInitial conditions from 44-mo half-life cases used.
doi:10.1371/journal.ppat.0030122.t003
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Limited Replenishment of HIV Reservoirconsidered the PPC to be the same as other viral sequences
with respect to replenishing the reservoir. However, even a
non-infectious PPC would be indicative of minimal viral
replication in the setting of HAART, because the PPC
comprises such a large portion of the plasma virus (and it
would be unlikely that all other plasma virus is produced
from viral replication with no release from the reservoir). All
other assumptions that were made would only artiﬁcially
increase the calculated maximum reservoir replenishment
rate. In particular, we assume that the PPC is ﬁrst present in
the plasma when we ﬁrst detect it experimentally, whereas it
may easily have been present in the patient much earlier. We
have also assumed that any PPC sequence found in resting
CD4
þ T cells is due to infection of that cell after initiation of
HAART. Clearly this is not the only possibility, as a PPC
sequence may have entered a resting CD4
þ T cell before
HAART was initiated.
By applying this approach to data derived from three
independent HIV-1-infected individuals on HAART who
exhibited a PPC, we have been able to quite conservatively
constrain the replenishment rate of the latent reservoir to be
at most on the order of 100 cells carrying replication-
competent virus per day. Given that the average size of the
latent reservoir is approximately one million cells [1], we have
therefore constrained the daily reservoir inﬂow to be
approximately 0.01%–0.1% of the total reservoir size for
the average HIV
þ patient on HAART. Our results predict a
substantial reduction in the reservoir inﬂow in the setting of
HAART compared to pre-HAART levels. While we could not
demonstrate a drastic reduction in reservoir inﬂow for pt.
148 due to the limited number of available sequences, we
were able to show in other patients that HAART reduces the
reservoir inﬂow by at least 10- to 20-fold from pre-HAART
levels. Given pt. 1549s treatment history of frequent blips
suggestive of low-level viral replication, that we are able to
predict a ;20-fold reduction in reservoir replenishment
suggests that HAART would reduce the reservoir replenish-
ment rate by even more in patients like pt. 135 and pt. 148,
who exhibit no signs of potential viral replication. Subse-
quent analyses and procurement of additional sequence data
may allow us to reduce the maximum replenishment rate of
the reservoir even further. Our present results, however, do
not establish whether or not there is any replenishment of the
latent reservoir by low-level viral replication in the setting of
HAART. Our analysis uses patient-derived data to conserva-
tively constrain the maximum replenishment rate of the latent
reservoir in the setting of HAART.
Of the three patients in our study, we detected the PPC in
the resting CD4
þ T cell compartment of one. We believe that
the infrequent detection of PPC in resting CD4
þT cells of our
study participants reﬂects the following: 1) few resting CD4
þ
T cells contain PPCs, and 2) replenishment of the latent
reservoir in the setting of HAART must be slow, which is
consistent with our results. Furthermore, while we can only
infer a maximum daily inﬂow into the latent reservoir (since
we cannot sequence the entire latent reservoir, but rather
only a sample of the latent reservoir at each time point), the
actual replenishment rate may easily be much lower than our
calculated maximum replenishment rate and may even be
zero. Finally, because the data have constrained the maximum
reservoir inﬂow rate to be small compared to the total
reservoir size, it may be that the ﬂow of new cells into the
reservoir does not signiﬁcantly affect the decay rate of the
latent reservoir in these patients (regime 1 versus regimes 2
and 3 described above).
The ﬁnding that the daily inﬂow into the reservoir is small
compared to the overall reservoir size suggests that the decay
of the reservoir in our patients (who have all been on HAART
for several years) is more likely determined by kout (the
intrinsic decay rate of latently infected cells) and not kin (new
entry into the reservoir). Our model, however, predicts that
the latent reservoir will eventually achieve a new steady-state
level of kin/kout. If there is an inﬂow into the latent reservoir,
despite HAART, further intensiﬁcation of HAART may
reduce the steady-state latent reservoir level or even lead to
eradication of the reservoir. Because our results indicate that
inﬂow into the reservoir must be very small and therefore
probably does not affect the reservoir decay rate, an
immediate beneﬁt from HAART intensiﬁcation may not be
apparent. In fact, our results suggest that HAART intensiﬁ-
cation could at best cause the latent reservoir to decay with a
half-life of on average 43.5 to 118 mo (Text S2).
The results of our analysis are important on a practical
level. It has been suggested that intensiﬁcation of HAART
may stop residual viral replication in the setting of standard
HAART and increase the decay rate of the latent reservoir
[18]. HAART intensiﬁcation poses a problem for physicians
and patients because intensiﬁed HAART also leads to
Table 4. Patient-Specific Maximum Daily Reservoir Inflow as a
Percent of the Total Latent Reservoir Size
Case
a Patient Reservoir
Half-Life
(Months)
Input
Period
(Days)
kin as
Percent
of Total
Reservoir
b
Add-One Estimator
kin as Percent of
Total Reservoir
c
1 135 44 90 0.0261 0.0162
148 44 90 0.0412 0.0243
154 44 90 0.0587 0.0506
2 135 44 120 0.0192 0.0121
148 44 55 0.0775 0.0417
154 44 897 0.0036 0.0035
3 135 6 90 0.0225 0.0140
148 6 90 0.0384 0.0214
154 6 90 0.0963 0.0765
4 135 6 120 0.0155 0.0099
148 6 55 0.0861 0.0402
154 6 897 0.0006 0.0005
5 135 ‘ 90 0.0261 0.0166
148 ‘ 90 0.0409 0.0245
154 ‘ 90 0.0924 0.0556
6 135 ‘ 120 0.0194 0.0125
148 ‘ 55 0.0834 0.0418
154 ‘ 897 0.0044 0.0043
aCase (based on assumptions used for the model):
1, 44-mo half-life, 90-d step input.
2, 44-mo half-life, full presence.
3, 6-mo half-life, 90-d step input.
4, 6-mo half-life, full presence.
5, steady-state, 90-d step input.
6, steady-state, full presence.
bBased on upper bound of 95% confidence interval for corresponding likelihood estimate
in Table 3.
cBased on most likely kin estimate from Table 3.
doi:10.1371/journal.ppat.0030122.t004
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Limited Replenishment of HIV Reservoirintensiﬁed drug toxicities such as lipodystrophy, hepatotox-
icity, and gastrointestinal symptoms [54–56]. Drug toxicity
not only leads to patient morbidity but also motivates non-
adherence with subsequent development of drug resistance
by the virus. Further analyses may enlighten the cost versus
potential beneﬁt of intensiﬁed HAART and hopefully max-
imize the clinical beneﬁt or treatment for patients with
minimal morbidity.
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